INTERNATIONAL MYELOMA SOCIETY

20th International Myeloma Society Annual Meeting

 

September 27 - 30, 2023 Athens
Close
N. Poster
Poster title
Applicant name
Status
  1-P The bone marrow stroma influences extrinsic apoptotic signaling and results in resistance to BCMA CAR-T cell induced cell death James Ackley Received Received
  2-P Impact of Bridging Therapy (BT) on outcome of Relapsed Refractory Multiple Myeloma (RRMM) with Ide-cel CAR T-cell therapy: Real-world Experience from the U.S. Myeloma CAR T Consortium Larry Anderson Received Received
  7-P Prognostic Impact of Corticosteroid and Tocilizumab Use on the Efficacy of Chimeric Antigen Receptor T-cell Therapy for Relapsed/Refractory Multiple Myeloma Bruno Costa Received Received
  8-NSP Co-designing a pilot patient support program (PSP) for a multiple myeloma (MM) therapy prior to listing on the Pharmaceutical Benefits Scheme Emma-Jane Furphy Received Received
  9-P Cellular dynamics following CAR T cell therapy are associated with response, resistance and cytokine release syndrome in relapsed/refractory myeloma Luise Fischer Received Received
  10-P Tumor-intrinsic features associated with progression-free survival (PFS) in patients (pts) with relapsed and refractory multiple myeloma (RRMM) treated with idecabtagene vicleucel (ide-cel) Samantha Sawh Received Received
  11-P Hematopoietic reconstitution and infections after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma are associated with pre-CAR-T bridging therapies Jan Frenking Received Received
  12-NSP Multiple Myeloma and Disparate Populations: The Path Forward Rebecca Lu Received Received
  13-NSP Multiple Myeloma: Validation of the Values and Preferences Elicitation Questionnaire- Cure and Survival Preference Scale (VPEQ-CSPS) Anastasiia Savchenko Received Received
  13-P Patterns of Cytokine Release Syndrome with Teclistamab in Relapsed/Refractory Multiple Myeloma with or without Prior T-Cell Redirection Therapy. Issam Hamadeh Received Received
  15-P A Novel CAR-T cell therapy targeting kappa myeloma antigen for the treatment of multiple myeloma Simon Harrison Received Received
  16-P DISPARITIES IN ACCESS AND PRACTICE PATTERNS OF BCMA-DIRECTED T-CELL ENGAGER (TCE) THERAPIES IN MULTIPLE MYELOMA: A GLOBAL PERSPECTIVE Hamza Hassan Received Received
  17-P Real-World Efficacy of CAR T-Cell Therapies: A HealthTree Cure Hubs Study of Multiple Myeloma Patients Jay Hydren Received Received
  24-P Early outcomes and therapy modification strategies in Multiple Myeloma patients treated with teclistamab, CD3XBCMA BITE; a single center experience. Swarup Kumar Received Received
  27-P Hotspot mutations in BCMA extracellular domain lead to differential susceptibility to anti-BCMA targeted immunotherapies Holly Lee Received Received
  31-P Idecabtagene vicleucel (ide-cel) vs standard regimens in patients with triple-classexposed (TCE) relapsed and refractory multiple myeloma (RRMM): KarMMa-3 subgroup analysis by prior lines of therapy Samantha Sawh Received Received
  32-P Ide-cel versus standard regimens in patients with triple-classexposed (TCE) relapsed and refractory multiple myeloma (RRMM): a KarMMa-3 analysis in the modified intention to-treat (mITT) population Michael Rowlands Received Received
  36-P REAL WORLD SINGLE CENTER EXPERIENCE OF LONG-TERM TOXICITIES WITH ANTI-BCMA CAR T-CELL THERAPY IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA Patrick Costello Received Received
  38-P Impact of Absolute Lymphocyte Count at pre-apheresis and pre-lymphodepletion on Chimeric Antigen Receptor (CAR)-T Therapy Outcomes in Relapsed Refractory Multiple Myeloma (RRMM) Noriko Nishimura Received Received
  39-P Vitamin D Deficiency and Clinical Outcomes with Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma Noriko Nishimura Received Received
  40-P Idecabtagene vicleucel (ide-cel) versus standard regimens in patients with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): a KarMMa-3 high-risk subgroup analysis Michael Rowlands Received Received
  43-P Leveraging wearable devices for remote patient monitoring facilitate earlier CRS detection following CAR-T therapy in relapsed/refractory multiple myeloma (RRMM): Early results from an IIT Sridevi Rajeeve Received Received
  47-P TRIAL IN PROGRESS: AN OPEN-LABEL, MULTICENTER, PHASE 1 STUDY OF IGM-2644 IN PARTICIPANTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM) Kevin Hart Received Received
  49-P Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel (Cilta-cel) for Relapsed/Refractory Multiple Myeloma (RRMM): Real World Experience Surbhi Sidana Received Received
  53-P Idecabtagene vicleucel retreatment response was characterized by poor activation, impaired cellular expansion, and limited cytolytic activity of chimeric antigen receptor T cells Stephanie Wolfe Received Received
  62-P Real-world evidence of bisphosphonates and denosumab for Multiple Myeloma Nieves Lopez-Muñoz Received Received
  64-P COMPARISON BETWEEN MRI AND PET/CT IN THE DIAGNOSIS OF PLASMACYTOMAS AND THEIR CLINICAL AND RADIOLOGICLA FOLLOW-UP Isabel Vicuna Received Received
  69-P Liquid biopsy monitoring is more sensitive than alternative techniques in extramedullary multiple myeloma Nicholas Bingham Received Received
  70-P Failure to Clear Circulating Tumor Cells After One Week of Daratumumab, Bortezomib and Dexamethasone is Associated with a Reduced Progression-Free Survival for Myeloma Patients Christian Bryant Received Received
  72-P Multiple Myeloma Patient Perceptions of Minimal Residual Disease Testing Jay Hydren Received Received
  73-P Modelling multiple myeloma using best clinical response to treatment to predict overall survival Adam Irving Received Received
  74-P Personalized mass spectrometry as a tool for minimal residual disease detection in the blood of myeloma patients Joannes Jacobs Received Received
  77-P High Sensitivity MRD Enumeration Using Combined Size Exclusion Isolation and Immunophenotyping Sherif Louis Received Received
  78-P MRDeep Study: Measurable Residual Disease rates in patients with Multiple Myeloma who achieved complete response in 2nd or 3rd lines of treatment. Rita Jaime Received Received
  79-P Impact of treatment effect on measurable residual disease (MRD) and progression-free survival (PFS): an aggregate data analysis from randomized clinical trials in multiple myeloma (MM) Bruno Paiva Received Received
  82-P Will survival improve by treating multiple myeloma patients at MRD relapse? The REMNANT study Anne-Marie Rasmussen Received Received
  84-P Use of Peripheral Blood for MRD Assessment During Maintenance Therapy: UTSW Experience Aishwarya Sannareddy Received Received
  86-P Patient and Haematologist Perspectives of Minimal Residual Disease Testing in Myeloma Silène ten Seldam Received Received
  89-P Evaluating dynamic changes in the serum free light chain ratio and its effect on risk of progression in smoldering multiple myeloma Theresia Akhlaghi Received Received
  90-P CLINICAL CHARACTERISTICS AND RISK OF PROGRESSION IN PATIENTS WITH MONOCLONAL GAMMOPATHY OF UNCERTAIN SIGNIFICANCE: LONG-TERM EXPERIENCE IN A SINGLE TERTIARY HOSPITAL. Elena Alejo Alonso Received Received
  92-P High Serum Free Light Chains levels in African Ancestry population screened for Monoclonal Gammopathy: implication for definition of FLC Reference Range Accounting for Renal Function and Race Luca Bertamini Received Received
  95-P Evolving M-spike and Risk of Progression in Smoldering Multiple Myeloma Malin Hultcrantz Received Received
  96-P Real world evidence of suboptimal humoral and cellular immune response to vaccination in ostensibly asymptomatic patients with precursor stage of multiple myeloma Yoshinobu Konishi Received Received
  99-P Phase II Trial of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma OMAR NADEEM Received Received
  101-P Single-cell RNA sequencing of 1.3 million plasma cells from patients with MGUS and SMM Romanos Sklavenitis-Pistofidis Received Received
  102-P Thrombotic Significance in Plasma Cell Disorders: Do associated clonal hematopoiesis of indeterminate potential (CHIP) mutations increase the risk? ritika vankina Received Received
  107-P The second revision of international staging system (R2-ISS) in newly diagnosed multiple myeloma patients: RWE settings Jelena Bila Received Received
  108-P Unravelling transplant-ineligible newly diagnosed multiple myeloma treatment in real-world practice in Spain. CARINAE Study. Miriam Gonzalez Received Received
  110-P Ixazomib maintenance in transplant-ineligible patients with newly diagnosed multiple myeloma: Final overall survival analysis from the TOURMALINE-MM4 study Meletios Dimopoulos Received Received
  111-P Overall survival trends in young ( 55 years) transplant-inaccessible multiple myeloma patients treated at a safety net hospital system Sharlene Dong Received Received
  112-P Determining the impact of multimorbidity in older patients initiating treatment for newly-diagnosed multiple myeloma using artificial intelligence/machine learning methods Nathanael Fillmore Received Received
  114-P In-class transition (iCT) from parenteral bortezomib (V) to oral ixazomib in multiple myeloma (MM) by age and frailty status: Updated subgroup analysis from the fully accrued US MM-6 study Saulius Girnius Received Received
  119-P The role of lenalidomide-dexamethasone therapy in elderly patients with multiple myeloma in clinical practice: comparison with bortezomib-based therapy Jihyun Kwon Received Received
  120-P Impact of exclusion from clinical trials in non-candidate transplant patients with newly diagnosed multiple myeloma Luis Gerardo Rodríguez-Lobato Received Received
  121-P Real World Outcomes of Undocumented Multiple Myeloma Patients: A Safety Net Hospital Experience Aishwarya Sannareddy Received Received
  124-P Therapeutic efficacy of ixazomib-based regimen in frail patients with newly diagnosed multiple myeloma based on the dynamic assessment of frailty HUA XUE Received Received
  127-P Bone marrow plasmacytosis 5 at time of autologous transplant influences survival outcomes in patients with standard risk cytogenetics Louis Williams Received Received
  128-P DARATUMUMAB- VTD VS VTD. PERI-TRANSPLANT EVALUATION. BELEN BALLINA MARTIN Received Received
  131-P Daratumumab (dara) as maintenance therapy after autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM): Results of a phase 2 study Azra Borogovac Received Received
  135-P Evaluation of the R2-ISS in real-world patients with newly diagnosed multiple myeloma: A nationwide cohort study by the Korean Multiple Myeloma Working Party (KMM 2202) Hyungwoo Cho Received Received
  136-P Phase I open-label single-arm study of dual targeting BCMA and CD19 FasTCAR-T cells (GC012F) as first-line therapy for transplant-eligible newly diagnosed high-risk multiple myeloma Qi Zhang Received Received
  140-P MULTIPLE MYELOMA IN LATIN AMERICA CANCER REGISTRY: THE MYLACRE STUDY Amanda Ferreira Received Received
  141-P Response and survival outcomes of daratumumab, lenalidomide, bortezomib and dexamethasone (D-RVD) induction in transplant-eligible newly diagnosed multiple myeloma (NDMM) patients Nisha Joseph Received Received
  142-P Stem cell collection after isatuximab or elotuzumab plus lenalidomide, bortezomib and dexamethasone in transplant-eligible multiple myeloma: single center data from the GMMG-HD6 and -HD7 trials Joseph Kauer Received Received
  143-P Treatment access among Black and White older adults with multiple myeloma: A SEER-Medicare analysis Matthew LeBlanc Received Received
  157-P How public policies have improved the overall survival of transplant eligible newly diagnosed multiple myeloma patients in the Chilean public health system Camila Peña Received Received
  158-P EXPERIENCE AT SON ESPASES UNIVERSITARY HOSPITAL WITH DARATUMUMAB, BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE (D-VRd) AS FIRST LINE TREATMENT IN MULTIPLE MYELOMA Lola Piquer Monsonis Received Received
  162-P Adding Plinabulin to pegfilgrastim to shorten neutropenia and improve quality of life peri-autologous hematopoietic cell transplant for multiple myeloma Gunjan Shah Received Received
  166-P Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) vs Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (DKRd) as Induction Therapy in Newly Diagnosed Multiple Myeloma Carlyn Rose Tan Received Received
  169-P CLINICAL FEATURES AND OUTCOME PATTERNS OF NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS WHO ARE CANDIDATE FOR TRANSPLANT: A SINGLE CENTER EXPERIENCE IN PARAGUAY Alana von Glasenapp Received Received
  178-P Evolution of the Multiple Myeloma Treatment Landscape in Portugal: a 5-year longitudinal analysis of treatment patterns in nationwide clinical practice Rui Bergantim Received Received
  179-P Altered Lipid Metabolism in IMiD/CELMoD Resistant Multiple Myeloma Confers Novel and Targetable Vulnerabilities Sarah Bird Received Received
  182-P Natural killer cells are active against myeloma cells with loss of tumor suppressor genes Olga Dashevsky Received Received
  187-P Therapeutically Targeting 19S Proteasome-associated Subunit PSMD1/Rpn2 in Multiple Myeloma Ting Du Received Received
  190-P Potent pre-clinical activity of EP300/CBP bromodomain inhibitor CCS1477 in multiple myeloma Kris Frese Received Received
  191-P Acquisition of venetoclax resistance is characterized by higher expression of anti-apoptotic regulators, less mitochondrial priming, and broader resistance to anti-MM agents. Mariateresa Fulciniti Received Received
  195-P Loss of GABARAP mediates resistance to immunogenic chemotherapy by altering protein trafficking of calreticulin on the cell surface Annamaria Gulla Received Received
  197-P Tissue factor as a new target for CAR-NK cell immunotherapy of multiple myeloma and triple-negative breast cancer Zhiwei Hu Received Received
  200-P MAP4K2 inhibition reinforces sensitivity to iberdomide in RAS-mutated MM through a CRBN-independent mechanism Suzanne Lentzsch Received Received
  203-P Rationale and design of three ongoing phase 1/2 trials of modakafusp alfa, an innate immunity enhancer, in patients with multiple myeloma: The iinnovate clinical development program Hira Mian Received Received
  205-P Heme promotes venetoclax resistance in multiple myeloma Remya Nair Received Received
  211-P Antiviral treatment improves outcome for individuals with multiple myeloma and other monoclonal gammopathies associated with Hepatitis B or C viruses. Alba Rodriguez Received Received
  212-P THE EFFECT OF UROLITHIN PRODUCTION BY GUT MICROBIOTA IN MULTIPLE MYELOMA Alba Rodríguez-García Received Received
  213-P COVALENT-101: Phase I Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL (NCT05153330) Courtney Follit Received Received
  214-P A phase 2 trial of leflunomide, pomalidomide, and dexamethasone for relapsed/refractory multiple myeloma Michael Rosenzweig Received Received
  219-P Investigating the Proteasome Stress Response as a Potential Therapeutic Target in Multiple Myeloma Cameron Van Cleave Received Received
  220-P Discovery of tumor-reactive T cell receptors by functional single cell interaction analyses in patients with newly diagnosed multiple myeloma Tim Robin Wagner Received Received
  225-P Uninvolved hypogammaglobulinemia was not a predictor of the infection risk in anti-CD38 chemotherapy Firas Al-Kaisi Received Received
  229-P Exposure-Response Analysis of Venetoclax in Combination with Carfilzomib and Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma Patients Mohamed Badawi Received Received
  230-P Pomalidomide, daratumumab, and dexamethasone after lenalidomide treatment in patients with relapsed or refractory multiple myeloma: final overall survival analysis of the phase 2 MM-014 study Stephanie Wolfe Received Received
  231-P ABBV-383, a BCMA-CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma: A Multicenter, Phase 1b Dose Optimization Study With Step-up Dosing Muhamed Baljevic Received Received
  232-P Effectiveness of anti-B-cell maturation antigen (BCMA)-targeting therapy after selinexor treatment Steve Mitchell Received Received
  233-P Physician perspectives regarding conventional marrow testing and MRD assessments to guide decision-making in myeloma Rahul Banerjee Received Received
  234-P DARATUMUMAB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS REAL WORLD EVIDENCE EXPERIENCES OF THE CROATIAN COOPERATIVE GROUP FOR HEMATOLOGIC DISEASES (KROHEM) Josip Batinic Received Received
  235-P Clinical and sociodemographic characterization of multiple myeloma patients with symptomatic relapse and/or refractory disease under treatment in Portugal: an observational, multicenter study Diogo Morais Received Received
  237-P Bendamustine (B) is associated with low response rates in heavily pretreated relapsed refractory multiple myeloma (RRMM) Natalie Callander Received Received
  241-P African American Relapsed/Refractory Multiple Myeloma patients have a Progression Free Survival benefit with selinexor treatment in the STORM study Craig Cole Received Received
  255-P Efficacy of a Second Autologous Stem Cell Transplant for Multiple Myeloma and Correlation with Response to Initial Transplant: A Single-Center Experience Barry Paul Received Received
  258-P CARFILZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS REAL WORLD EVIDENCE EXPERIENCES OF THE CROATIAN COOPERATIVE GROUP FOR HEMATOLOGIC DISEASES (KROHEM) Davor Galusic Received Received
  264-P A Phase 1b Study of Isatuximab and Bendamustine for Triple-Class Refractory Multiple Myeloma Scott Goldsmith Received Received
  273-P Isatuximab monotherapy or combination therapy with dexamethasone in older adult patients with relapsed/refractory multiple myeloma: a single institution experience Masaki Iino Received Received
  276-P Healthcare Resource Utilization and Costs Among Patients With Relapsed/Refractory Multiple Myeloma Treated With Chimeric Antigen Receptor-T (CAR-T) Cell Therapy Mary Baugh Received Received
  277-P Venetoclax Versus Bortezomib, in Combination with Daratumumab and Dexamethasone, in Patients With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma Amanda Ward Received Received
  278-P Estimating the Size of Patients With Relapsed/Refractory Multiple Myeloma Treated With 1-3 and 4 or More Prior Lines of Therapy in the United States Mary Baugh/MedThinkSciCom Received Received
  279-P Efficacy and Safety of Carfilzomib, Lenalidomide, and Dexamethasone Versus Ixazomib, Lenalidomide, and Dexamethasone in Real world Patients with Relapsed/Refractory Multiple Myeloma: KMM2004 study Ho-Jin Shin Received Received
  280-P A single-center treatment sequencing analysis in patients with relapsed/refractory multiple myeloma (RRMM) swarup kumar Received Received
  287-P Isatuximab Plus Pomalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma in Real Life Context in France: IMAGE Subgroup Analysis Based on Subgroups of Interest Kirsty Lee Received Received
  289-P The efficacy and safety of Prednisone, Cyclophosphamide, Doxorubicin and Carmustine (PCAB) in relapsed/refractory multiple myeloma in the era of novel therapy, including as a bridge to CAR-T therapy. Eric Wenlong Li Received Received
  291-P Outcomes of Third-Line Therapy in Multiple Myeloma Patients: a Report from the Canadian Myeloma Research Group (CMRG) Martha Louzada Received Received
  293-P Real-World Treatment Patterns and Outcomes in Lenalidomide Refractory Multiple Myeloma Patients in Europe: A Real-World Survey Emily Luke Received Received
  296-P LIGHTHOUSE: MELFLUFEN, DARATUMUMAB, AND DEXAMETHASONE VERSUS DARATUMUMAB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA REFRACTORY TO AN IMID AND A PROTEASOME INHIBITOR OR WITH =3 PRIOR LINES OF THERAPY Megan Ruzomberka Received Received
  302-P ANCHOR (OP-104): MELFLUFEN PLUS DEXAMETHASONE AND DARATUMUMAB OR BORTEZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)FINAL EFFICACY AND SAFETY RESULTS Megan Ruzomberka Received Received
  304-P TRIPLE CLASS REFRACTORY MULTIPLE MYELOMA: EFICACY OF THE NEW IMMUNOTHERAPIES AND NEW UNMET MEDICAL NEED Borja Puertas Received Received
  305-P DREAMM-20: A STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF BELANTAMAB FOR THE TREATMENT OF MULTIPLE MYELOMA (MM) WHEN USED AS MONOTHERAPY AND IN COMBINATION TREATMENTS Michael Checkoway Received Received
  306-P Final results of a Phase 1b study of subcutaneous isatuximab administration by an on-body delivery system (OBDS) plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma (RRMM) Mackenzie Baciuska Received Received
  308-P Superiority of daratumumab plus lenalidomide and dexamethasone in first and second relapse in multiple myeloma patients: a real-world single center retrospective analysis Michel Delforge Received Received
  314-P Bendamustine Salvage for Relapsed Refractory Multiple Myeloma: A retrospective analysis of outcomes in heavily pretreated patients. Aakanksha Singh Received Received
  316-P NK cell kinetics predict outcome in the multiple treated with elotuzumab, lenalidomide plus dexamethasone (ERd): a subanalysis in Japanese multicenter observation for once monthly ERd study. Kazuhito Suzuki Received Received
  323-P A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone Versus Elotuzumab, Pomalidomide, and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma Steve Mitchell Received Received
  329-P A phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma Andrew Yee Received Received
  335-P Small nucleotide, copy number and structural variants cooperate to hijack driver genes in extramedullary progression of myeloma Nicholas Bingham Received Received
  337-P The germinal center origin and progression of MM is captured by 83 Vk*MYC MM transplantable lines that share overlapping genomic diversity with human disease Marta Chesi Received Received
  342-P Genomic Profiling of Treated High-Risk Smoldering Multiple Myeloma Benjamin Diamond Received Received
  348-P ADAR1-regulated cytoplasmic dsRNA-immune sensing pathway is a novel mechanism of lenalidomide resistance in multiple myeloma Mun Yee Koh Received Received
  349-P A retrospective assessment of biologically relevant genomic perturbations and variants of unknown significance in a cohort of plasma cell disorder at our institution; a single center experience Swarup Kumar Received Received
  351-P Are genomic lesions of Cereblon pathway genes sufficient to explain clinical relapses from IMiD-based treatment in multiple myeloma (MM)? Lisa Leypoldt Received Received
  354-P Whole genome sequencing reveals significant genetic admixture in multiple myeloma patients, impacting assessment of etiology Kylee Maclachlan Received Received
  355-P A novel genomewide RNA-Targeting CRISPR/Cas13 Screen Identifies a Plasma Cell-Specific long non-coding RNA (LncRNA) Essential for Myeloma Cell Growth Domenico Maisano Received Received
  356-P Effect of Amplification or Gain of 1Q21 in patients with Multiple Myeloma treated with Dartumumab Irene Zamanillo Herreros Received Received
  357-P Individualized Risk in Newly Diagnosed Multiple Myeloma Francesco Maura Received Received
  358-P Myeloma at a younger age presents with distinctive clinical and molecular features Mateo Mejía saldarriaga Received Received
  359-P Non-Paraskeletal Extramedullary Disease Is Associated with high rates of high risk cytogenetic alterations and has a distinct transcriptional profile Mateo Mejia Saldarriaga Received Received
  371-P Mutant-specific pharmacological inhibition of KRAS in multiple myeloma and functional genomics studies to identify mechanisms regulating myeloma cell response vs. resistance to KRAS inhibition. Torsten Steinbrunn Received Received
  372-P Transcriptomic expression of BMP-2, BMP-6 and Smad6 genes in newly diagnosed and relapsed multiple myeloma patients Panagiotis Stoikos Received Received
  373-P Functional genomics of genes residing in the minimally deleted chromosome 17p13 region in multiple myeloma: therapeutic implications Phaik Ju Teoh Received Received
  376-P Genomic and transcriptional profiling stratifies myeloma models into two clusters with distinct risk signatures and drug responses Jing Zhang Received Received
  380-P Immunological Aging Is Associated with Worse Clinical Outcome in Elderly Newly Diagnosed Multiple Myeloma Patients Wassilis Bruins Received Received
  381-P Mezigdomide (CC-92480) activates innate and adaptive immune populations in the bone marrow microenvironment of heavily pre-treated multiple myeloma patients Lucia Chen Received Received
  382-P Dysregulations of the immune tumor microenvironment in multiple myeloma Danka Cholujova Received Received
  385-P Single cell RNA sequencing reveals activated translation machinery in memory T cells among exceptional responders to lenalidomide Joselle Cook Received Received
  388-P An IL-1 driven neutrophil-stromal cell axis fosters a BAFF-rich tumor-supportive bone marrow environment in multiple myeloma patients Tom Cupedo Received Received
  390-P The differentiation and expansion of T cell clonotypes in the bone marrow following ASCT: insights from the Phase 2 CARDAMON study Kane Foster Received Received
  391-P Checkpoint inhibitor PD-1H/VISTA mediates its effects on osteoclast cytoskeleton in myeloma bone disease via c-Src/Rac1 signaling Suzanne Lentzsch Received Received
  394-P Proteomic Analysis to Discover Bone Marrow Plasma Biomarkers Predicting Outcome Following Autologous Stem Cell Transplantation in Multiple Myeloma Patients Diane Jelinek Received Received
  399-P Isatuximab Promotes Immune Activation in the Bone Marrow Microenvironment of Patients with High Risk Smoldering Multiple Myeloma Mario L. Marques-Piubelli Received Received
  400-P An immune atlas of the dysfunctional cellular and antibody response to COVID-19 vaccination in patients with multiple myeloma Esperanza Martín-Sánchez Received Received
  406-P Development of a 3D bioreactor model using a perfusion bioreactor to study osteocyte progenitor cells and the Involvement of single ECM molecules in Multiple Myeloma Bone Disease Wyonna Darleen Rindt Received Received
  411-P Large-scale single-cell dissection of immune dysregulation in patients with monoclonal gammopathies Romanos Sklavenitis-Pistofidis Received Received
  413-P Inflammatory markers characterize neutrophils and C1q TAMs in the day 100 bone marrow aspirate post ASCT of patients with early progression Caleb Stein Received Received
  420-P Unusual Presentations of Amyloidosis: A Multicase Analysis Highlighting Diverse Clinical Manifestations and Diagnostic Challenges Ashwathy Pillai Received Received
  421-P Reference interval of free light chain ratio for patients on chronic hemodialysis Pablo Bustamante Received Received
  422-P Impact of early response and CXCR4 mutation status on progression-free survival with ibrutinib-based therapy in Waldenström macroglobulinemia: A post hoc analysis of the iNNOVATE trial Colleen McGowan Received Received
  424-P Partial response or better at 6 months is not shown to be a prognostic indicator of progression-free survival in Waldenström macroglobulinemia treated with acalabrutinib: A post hoc analysis Jorge Castillo Received Received
  430-P INCIDENCE OF PRIMARY PLASMA CELL LEUKEMIA WITH THE NEW DIAGNOSTIC CRITERIA. Virginia Jano Received Received
  433-P Targeting Free Light Chain Secretion Via Botulinum Neurotoxin Is a Novel Therapeutic Strategy in AL Amyloidosis By Inducing a Terminal Unfolded Protein Response Emre Karayol Received Received
  436-P Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Patients with Amyloid Light Chain (AL) Amyloidosis Paolo Lopedote Received Received
  438-P Castleman disease: histopathologic reclassification, clinical characteristics and endpoints in a reference center in Mexico DEBORAH MARTINEZ Received Received
  441-P Soluble Urokinase Plasminogen Activator Receptor (SuPAR) in patients with plasma cell dyscrasias, a pilot study Agne Paner Received Received
  448-P Impact of Molecular Cytogenetic Abnormalities on the Risk of Disease Progression in Solitary Bone Plasmacytomas udit yadav Received Received
  449-P Role of Education and Empowerment in Multiple Myeloma patients Jay Hydren Received Received
  451-P Association between Dexamethasone Exposure and Visually Significant Cataracts in Myeloma Rahul Banerjee Received Received
  452-P Financial Toxicity and Time Toxicity among Patients with Multiple Myeloma Rahul Banerjee Received Received
  453-P Randomized Phase II Study of Digital Life Coaching during Stem Cell Transplantation for Myeloma Rahul Banerjee Received Received
  459-P A Randomized, Controlled Phase 2 Trial of Uproleselan, an E-Selectin Inhibitor, vs Placebo to Reduce GI Toxicity in Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplant Zachary Crees Received Received
  461-P An overview of challenges experienced in multiple myeloma: perspectives of hematologist-oncologists and specialist nurses Maya Gilbert Received Received
  463-P Patient Characteristics and Burden in Lenalidomide Refractory Multiple Myeloma Patients in Europe: A Real-World Survey Francesca Gay Received Received
  464-P Treatment Decision-Making in Patients Diagnosed With Multiple Myeloma Mary Baugh Received Received
  466-P PERIPHERAL AND SEVERE AUTONOMIC NEUROPATHY CHARACTERIZED BY DIZZINESS, ORTHOSTATIC HYPOTENSION AND WEIGHT LOSS CAUSED BY BORTEZOMIB. Danielle Bradshaw Received Received
  467-P Dietary risk factors for monoclonal gammopathy of undetermined significance in a racially diverse National Health and Nutrition Examination Survey (NHANES) case-control study Urvi Shah Received Received
  470-P Single center experience of denosumab for hypercalcemia in multiple myeloma Matthew Lei Received Received
  473-P Real-world evidence of Statins and Oral Antidiabetics for Multiple Myeloma Nieves Lopez-Muñoz Received Received
  476-P More efficient delivery of high-cost standard-of-care therapies in relapsed multiple myeloma using real-time feedback of patient-reported outcome measures: the MY-PROMPT-2 trial Elizabeth Moore Received Received
  478-P Humanistic, Clinical, and Economic Burden in Patients with Relapsed or Refractory Multiple Myeloma on Second Line or Higher Therapy: A Systematic Literature Review Erin Cook Received Received
  479-P Disparities in Clinical Trial Enrolment and Survival Outcomes by Socio-economic Class in Multiple Myeloma Amrutha Sridhar Received Received
  481-P The effect of touch on pain, anxiety and the patient experience during bone marrow biopsies Anna Schaal Received Received
  482-P Dietary habits correlate with myeloma pathogenesis and treatment outcome in multiple myeloma Lilli Sester Received Received
  483-P A Whole Foods Plant-based Weight Loss Intervention Improves Metabolic and Immune Biomarkers in MGUS/SMM Patients as well as Progression Trajectory in a Subset The NUTRIVENTION Trial Urvi Shah Received Received
  484-P Successful incorporation of ePRO using PROMIS-29 into standard of care after hematopoietic stem cell transplant and chimeric antigen receptor T cell therapy for plasma cell dyscrasias. Gunjan Shah Received Received
  486-P Clinical significance of baseline body mass index and its trajectory during triplet induction therapy in newly diagnosed multiple myeloma Ram Prakash Thirugnanasambandam Received Received
  487-P Adherence to patient-reported symptom monitoring and subsequent clinical interventions for patients with Multiple Myeloma in outpatient care: A longitudinal observational study Ella Willenbacher Received Received
  488-P Expert in the Loop - AI assisted generation of Real-World-Evidence Wolfgang Willenbacher Received Received
  500-P MULTIPLE MYELOMA: Do we have scales to assess the risk of Thromboembolic Events (TEV)? Dianis Escorcio Received Received
  504-P A Phase II Study of Isatuximab, Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial) Betsy ODonnell Received Received
Tel.: +34 91 736 2385
LOCAL TIME
Contact: Katarina Gluic
Hours: Mon-Thu 8:30-17:00 Fri 8:30-15:00
10:47
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments

 

20th International Myeloma Society Annual Meeting

 

September 27 - 30, 2023 Athens
Virtual Poster Gallery
Search and consult posters online
in an exclusive section
for each poster
    ACTIVE FROM 27/09/2023 TO 27/09/2023
Poster
Gallery
Upload
Poster
Featured Poster
Vote poster
Poster Discussion
Forum
                  




PosterSessionOnline
Logo Draft
Logo Cert